SwissVisio Montchoisi
Lausanne, Canton of Vaud, 1006, Switzerland
NCT Number: NCT04381611
The study is an observational analysis of patients' medical data recorded in a large-scale register, both retrospective (for patients operated and data recorded before 2018) and prospective (for data collected after 2018) in nature.Patients' medical data contained in the register will be analysed to determine the efficacy of the treatments they received during their follow-up at the investigation centre.
Interested in participating?
Request Info1 year–100 year
All sexes
Observational
Lausanne, Canton of Vaud, 1006, Switzerland
This study involves the creation and analysis of a large-scale register including all patients suffering from glaucoma, currently and previously followed-up and treated at a single tertiary centre in Lausanne, Switzerland. The design of the study is longitudinal, observational and comparative. Patients are recruited retrospectively if they attended the research centre before September 2018, and prospectively if they attend the centre from this month onwards. Their inclusion does not affect their care, treatment choice or follow-up. All data of recruited patients is be kept in their medical notes until a specific analysis is launched. Data is then exported from their medical notes into a coded database for analysis. At the end of each analysis session (defined as the publication of the related article), all exported data is fully anonymised.
Data analysis will aim to assess the long-term efficacy, safety profile, and factors predictive of success/failure of treatments performed.
To ensure the quality of all included data, health-related information will be extracted directly from the medical notes and coded into the register by a Clinical Research Associate. Conformity of the process and recorded data will be confirmed by regular internal auditing. For quality assurance the Ethics Committee may visit the research sites. Direct access to the source data and all project related files and documents must be granted on such occasions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 month
Final Intra Ocular Pressure <20% compared to baseline
Time frame: 12 month
Variation of RNFL before and after treatment ( laser, surgery, drug..)
Time frame: 12 month
Visual Field MD variation before and after treatment ( laser, surgery, drug..)
Time frame: 12 months
Visual Field MD variation before and after treatment ( laser, surgery, drug..)
Time frame: 12 month
Number of operations undertaken by each patient
Time frame: 12 month
Number of patients undertaking different types of ocular procedures ( deep sclerectomy, cataract, LPI, SLT,...)
Time frame: 12 month
Number of molecules used by each patient (e.g Cosopt: 2 molecules, Xalatan: 1...)
Time frame: 12 month
variations of these measurements before and after procedure ( surgery or laser)
Time frame: 12 month
variations of these measurements before and after procedure ( surgery or laser)
Time frame: 12 month
variations of these measurements before and after procedure ( surgery or laser)
Dr. Kaweh Mansouri
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06689696
Eye Diseases, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Fullerton, California, United States
View Trial DetailsNCT06685211
Eye Diseases, Glaucoma
Palo Alto, California, United States
View Trial DetailsNCT07063537
Eye Diseases, Glaucoma
Halifax, Nova Scotia, Canada
View Trial DetailsNCT06434155
Eye Diseases, Glaucoma
Asyut, Egypt
View Trial Details